{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-300042","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2023-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.026781+00:00","generated_at":"2026-06-07T09:40:51.171890+00:00","sec_items":["1.01","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioMarin settles with Elliott; appoints 3 new directors, forms strategic review committee","bullets":["Board expanded to 15 directors; appoints Barbara Bodem, Athena Countouriotis, Mark Enyedy as independent directors effective Dec 27, 2023.","New Strategic and Operating Review Committee chaired by Richard Meier; includes CEO Alexander Hardy and Maykin Ho; to review business, strategy, and capital allocation.","Cooperation agreement with Elliott includes standstill, voting commitments, and mutual non-disparagement; Elliott supports the changes.","Company commits to holding an investor day in 2024 after committee recommendations; Elliott entered into information-sharing agreement for JPM conference and earnings."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-300042","json":"https://secwatch.observer/filing/0001193125-23-300042.json","markdown":"https://secwatch.observer/filing/0001193125-23-300042.md","text":"https://secwatch.observer/filing/0001193125-23-300042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000119312523300042/0001193125-23-300042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000119312523300042/d488420d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T09:40:51.171890+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"73ccf216d5","claim":"Barbara Bodem was appointed as director at BIOMARIN PHARMACEUTICAL INC.","evidence_excerpt":"On December 20, 2023, the size of the Board was expanded from 12 to 15 members in order to allow for the Board to appoint each of Ms. Bodem, Dr. Countouriotis and Mr. Enyedy to serve as a member of the Board, effective on December 27, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000119312523300042/0001193125-23-300042-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"96bc12b5c5","claim":"Athena Countouriotis was appointed as director at BIOMARIN PHARMACEUTICAL INC.","evidence_excerpt":"On December 20, 2023, the size of the Board was expanded from 12 to 15 members in order to allow for the Board to appoint each of Ms. Bodem, Dr. Countouriotis and Mr. Enyedy to serve as a member of the Board, effective on December 27, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000119312523300042/0001193125-23-300042-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"c1535c4707","claim":"Mark Enyedy was appointed as director at BIOMARIN PHARMACEUTICAL INC.","evidence_excerpt":"On December 20, 2023, the size of the Board was expanded from 12 to 15 members in order to allow for the Board to appoint each of Ms. Bodem, Dr. Countouriotis and Mr. Enyedy to serve as a member of the Board, effective on December 27, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000119312523300042/0001193125-23-300042-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"35786d8da85bbad9d51e1ca8dead49965e5822e7","claim":"BIOMARIN PHARMACEUTICAL INC entered into Cooperation Agreement with Elliott Investment Management L.P., Elliott Associates, L.P. and Elliott International, L.P. (collectively, “Elliott”) (effective 2023-12-20).","evidence_excerpt":"On December 20, 2023, BioMarin Pharmaceutical Inc. (the “Company”) announced that it had entered into a Cooperation Agreement (the “Cooperation Agreement”) with Elliott Investment Management L.P., Elliott Associates, L.P. and Elliott International, L.P. (collectively, “Elliott”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000119312523300042/0001193125-23-300042-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Elliott Investment Management L.P., Elliott Associates, L.P. and Elliott International, L.P. (collectively, “Elliott”)"},{"label":"Effective","value":"2023-12-20"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}